Arizona-based biotech startup BioLab Sciences

     announces patent for regenerative tissue therapy, MyOwn Skin™


SCOTTSDALE, Ariz., Oct. 24, 2018 /PRNewswire/ — BioLab Sciences, an innovator in regenerative medicine technologies, today announced its exclusively licensed technology for MyOwn SkinTM, a painless, non-surgical procedure, which leverages a patient’s own skin to produce full-thickness skin grafts in 5-7 days.

MyOwn SkinTM is a revolutionary approach that uses a patient’s own skin to accelerate healing of chronic wounds, burns, diabetic foot ulcers and other difficult-to-heal wounds. By utilizing a small skin sample, this regenerative approach allows the body to heal itself and is less likely to face infection or rejection.

“In the United States alone, chronic wounds affect 6.5 million patients,” said Bob Maguire, BioLab Sciences CEO. “Our advanced, tissue-biomanufacturing approach offers a viable, effective solution for skin regeneration and repair. This innovative strategy has shown to accelerate the healing of damaged soft tissue and improve wound-care outcomes.”

This autologous strategy to wound care is non-invasive, improves recovery time, and eliminates potential rejection. BioLab’s impressive portfolio of regenerative products includes its amnion-derived fluid products, Fluid FlowTM and Amnio RestoreTM and its amniotic allograft membrane product Membrane PatchTM, an amnion membrane allograft composed of a connective tissue matrix that regenerates soft tissue while inhibiting inflammation and scarring. BioLab Sciences also offers a comprehensive wound care kit that provides physicians with the necessary tools to help patients recover quickly from diabetic ulcers, burns and other traumatic external wounds, as well as its Amnio Breathe Nebulizer bundled package designed to deliver a topical treatment directly onto a patient’s respiratory system …

View original content to download multimedia: